Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea

Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.05.13.20094193; this version posted June 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea Min Seo Kim, MD, Soon-Woo Jang, MD, KMD, Yu-Kyung Park, MD, Bong-Ok Kim, MD, PhD, Tae-Ho Hwang, DSS, PhD, Seok Ho Kang, MD9, PhD, Won Jun Kim, MD, Park Sung Kyu, MD, Hea-Woon Park, MD, PhD, Wonjong Yang, MD, Joonyoung Jang, MD, Min Ho An, MD The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.